# Tumor Lysis Syndrome: Comprehensive Management and Nephrologist’s Perspective

**Written for:** Experienced nephrologist audience from onco-nephrology perspective **Board-Review Depth:** Yes \| **Practical Management:** Yes

------------------------------------------------------------------------

## DEFINITION & CLASSIFICATION

### Cairo-Bishop Criteria (2004) — Laboratory & Clinical TLS \[1\]

**Laboratory TLS:** Requires ≥2 of the following abnormalities **within 3 days before or 7 days after chemotherapy initiation:**

| Parameter | Threshold |
|----|----|
| **Uric acid** | ≥8.0 mg/dL OR 25% increase from baseline |
| **Potassium** | ≥6.0 mmol/L OR 25% increase from baseline |
| **Phosphorus** | ≥4.5 mg/dL (pediatric) or adjusted for age/sex (adult) OR 25% increase from baseline |
| **Calcium** | ≤7.0 mg/dL OR 25% decrease from baseline |

**Clinical TLS:** Laboratory TLS + ≥1 clinical manifestation: - **Acute kidney injury:** Cr ≥1.5 × upper limit normal - **Cardiac arrhythmia** or sudden death - **Seizure** - **Other clinical complications** of organ dysfunction

**Key Limitation of Cairo-Bishop:** Criteria were developed for chemotherapy-initiated TLS; **spontaneous TLS** (from tumor necrosis before chemo) is not captured but clinically important (see below).

------------------------------------------------------------------------

## EPIDEMIOLOGY & RISK STRATIFICATION

### Tumor-Specific Risk \[1\]

**High-Risk Tumors (30–50% incidence):** - **Burkitt lymphoma** — most common, highest risk - **Acute lymphoblastic leukemia (ALL)** — children especially high-risk - **Acute myeloid leukemia (AML)** with high WBC (\>100,000) - **Lymphoblastic lymphoma** - **Primary CNS lymphoma**

**Intermediate-Risk Tumors (5–30%):** - **Diffuse large B-cell lymphoma (DLBCL)** — varies by bulk and stage - **Chronic lymphocytic leukemia (CLL)** — especially with targeted therapy (venetoclax) - **Hodgkin lymphoma** — less common than NHL - **Small lymphocytic lymphoma (SLL)** - **Acute leukemia with lower tumor burden**

**Low-Risk Tumors (\<5%):** - Solid tumors (lung, colorectal, breast, etc.) - Low-grade lymphomas (follicular, marginal zone) - Chronic myeloid leukemia (CML) — except blast phase

### Patient-Specific Risk Factors

| Factor | Impact |
|----|----|
| **Baseline renal function** | eGFR \<60 dramatically ↑ risk (cannot clear uric acid/phosphate) |
| **Baseline uric acid** | Baseline \>6 mg/dL → higher risk of rapid rise |
| **Dehydration/volume status** | Prerenal component worsens outcomes |
| **Advanced age** | \>65 years associated with worse outcomes |
| **Prior TLS episode** | Known history → expect higher risk in subsequent therapy |
| **Large tumor burden** | High LDH, high WBC, massive lymphadenopathy |

------------------------------------------------------------------------

## PATHOPHYSIOLOGY OF TUMOR LYSIS SYNDROME

### The Metabolic Cascade \[1\]

    Tumor cell death (rapid, massive)
        ↓
    Release of intracellular contents:
    ├─ Potassium (K) — from cytoplasm (ICF K++ ~140 mEq/L)
    ├─ Phosphate (PO4) — from nuclei, mitochondria
    ├─ Uric acid — from DNA/RNA nucleotides
    └─ Other: myoglobin, LDH, urea, creatinine
        ↓
    Acute metabolic derangements:

    1. HYPERKALEMIA (K >6.0 mmol/L)
       └─ Mechanism: K+ influx from dying cells exceeds renal excretion capacity
       └─ Effect: Cardiac arrhythmias (peaked T-waves, AV block, VF), muscle weakness
       └─ Timeline: Hours to days

    2. HYPERPHOSPHATEMIA (PO4 >4.5 mg/dL)
       └─ Mechanism: PO4 release + reduced renal excretion (if AKI)
       └─ Secondary: Ca × PO4 product ↑ → precipitation in soft tissues
       └─ Effect: Hypocalcemia (symptomatic if severe: tetany, seizure)

    3. HYPOCALCEMIA (Ca <7.0 mg/dL)
       └─ Mechanism: Secondary to Ca × PO4 deposition; also PO4 chelation
       └─ Effect: QT prolongation, tetany, seizures (IF symptomatic)
       └─ **KEY POINT:** Avoid treating asymptomia hypocalcemia (worsens CaPO4 precipitation)

    4. HYPERURICEMIA (uric acid >8.0 mg/dL)
       └─ Mechanism: Massive nucleic acid catabolism → xanthine → uric acid
       └─ Renal toxicity: Uric acid crystals precipitate in distal tubules/collecting duct
       └─ Cascade: Crystal nephropathy → tubular obstruction → ↑ back-pressure → AKI
       └─ **Timing:** Uric acid rise lags K, PO4 (peaks day 2–3)

### Uric Acid Cascade (Detailed)

**Why uric acid causes AKI:**

1.  **Solubility problem:** Uric acid poorly soluble in tubular fluid (pKa 5.75)
2.  **Low urine pH** → more undissociated uric acid → precipitates
3.  **High urine uric acid concentration** (from massive release) + dehydration → crystal formation
4.  **Xanthine & alloxuric crystals** also precipitate (if on allopurinol)
5.  **Tubular obstruction** → back-pressure on glomerulus → prerenal AKI
6.  **Oxidant stress** from uric acid metabolism → tubular cell injury

------------------------------------------------------------------------

## PREVENTION OF TUMOR LYSIS SYNDROME \[1\]

**Golden Rule:** Prevention is infinitely easier than treating established TLS. Begin **immediately upon diagnosis** of high-risk tumor.

### Risk Stratification & Prevention Strategy

    Newly diagnosed high-risk hematologic malignancy
        ↓
    RISK ASSESSMENT (see table above):
    ├─ HIGH-RISK patient + HIGH-RISK tumor → Aggressive prevention
    ├─ HIGH-RISK patient + INTERMEDIATE tumor → Standard prevention
    └─ LOW-RISK patient + LOW-RISK tumor → Minimal prevention
        ↓
    INITIATE PREVENTION BEFORE FIRST CHEMO DOSE:

### Component 1: Aggressive IV Hydration \[1\]

**Goal:** Maximize urine output & dilute intratubular toxic substances.

| Target | Dose | Duration | Monitoring |
|----|----|----|----|
| **Urine output** | 100–200 mL/hr (or 200–300 mL/m²/hr) | Continuous from pre-chemo through post-chemo | Hourly UOP; Foley catheter indicated |
| **IV fluid rate** | 2–3 L/m²/day (equivalent to ~100–150 mL/kg/day) | 24–48 hr pre-chemo, during, 48–72 hr post-chemo | Total daily I/O; weight; orthostatics |
| **Fluid type** | **Normal saline (0.9% NaCl)** — preferred | Continuous | Check Na, Cl; avoid hyponatremia |
| **Alternative** | If fluid overload is a concern, individualize fluid volume and rate with repeated perfusion and congestion assessment; hypotonic saline is not a treatment for fluid overload | Reduced intensity hydration | Reassess if Cr rises despite hydration |

**Rationale for NS:** Normal saline is preferred over hypotonic fluids because: - Maintains osmolality → reduces cellular water shift → limits hyperkalemia - Maintains renal perfusion pressure - Avoids hyponatremia (which can occur with ½ NS + SIADH from malignancy)

**Complications of aggressive hydration:** - **Volume overload** → pulmonary edema, HTN (especially in AML with leukostasis risk) - **Hyponatremia** (if dilute fluids used) → seizure risk - **Electrolyte wasting** (from forced diuresis)

**Assessment:** Daily weights, JVD, lung auscultation; adjust if volume overload develops.

### Component 2: Xanthine Oxidase Inhibitor — Allopurinol

**Allopurinol (Zyloprim):** Blocks conversion of hypoxanthine → xanthine → uric acid

**Dosing:** - **Standard:** 300 mg daily (in high-risk) or 600 mg daily (very high-risk) - **Renal dose:** Reduce dose if eGFR \<30 (allopurinol itself nephrotoxic in renal failure) - **Onset:** 24–48 hours (slow; starts blocking NEW acid production) - **Limitation:** Does NOT clear existing uric acid; slow onset makes it **NOT ideal as monotherapy**

**Mechanism of AKI with allopurinol:** Xanthine crystals (intermediate product) also precipitate in tubules — “converting one crystal problem to another”

**Current role:** **Allopurinol is secondary agent** now; rasburicase (urate oxidase) is preferred.

### Component 3: Urate Oxidase (Rasburicase) — FIRST-LINE \[1\]

**Rasburicase (Elitek):** Recombinant urate oxidase; **catalyzes conversion of uric acid → allantoin** (5–10× more soluble than uric acid)

**Mechanism:** Uric acid → \[urate oxidase\] → Allantoin + H2O2 (H2O2 rapidly degraded by catalase)

**Dosing:**

    DOSE:
    ├─ Standard: 0.2 mg/kg IV over 30 minutes
    ├─ Range: 0.15–0.25 mg/kg (single or divided doses)
    ├─ Repeat: Usually single dose sufficient; repeat if uric acid remains >8 mg/dL at 4 hr
    └─ Infusion time: ≥30 minutes (do NOT push)

    TIMING:
    ├─ Initiate: BEFORE chemotherapy (12–24 hr before preferred)
    ├─ Can use: Up to 7 days post-chemo if uric acid rising
    └─ Effect: Rapid (uric acid begins to fall within 4 hr; half-life of urate oxidase ~6 hr)

**Efficacy:** Rasburicase reduces serum uric acid by 80–90% within 4 hours \[1\]

**Advantages over allopurinol:** 1. **Rapid onset** (hours vs. days) 2. **Clears existing uric acid** (vs. allopurinol which only blocks new production) 3. **Does NOT produce xanthine crystals** (allantoin is soluble) 4. **Preferred for immediate TLS risk**

**Critical Contraindications:**

| Contraindication | Reason | Alternative |
|----|----|----|
| **G6PD deficiency** | Rasburicase produces H2O2 → hemolysis in G6PD-deficient RBCs | Check G6PD before rasburicase (esp. if African descent, Mediterranean, Asian heritage); use allopurinol if G6PD- |
| **Severe allergy** | IgE-mediated reaction to bacterial-derived enzyme | Premedicate with diphenhydramine + acetaminophen; consider alternative |

**Cost:** ~\$500–\$1000 per dose (significantly more expensive than allopurinol); often requires prior authorization

Rasburicase continues to degrade urate after blood collection and can cause a falsely low result unless the specimen is handled correctly. Coordinate with the laboratory: use a prechilled heparin tube, immediately maintain the sample in an ice-water bath, centrifuge cold, and analyze the chilled plasma within four hours of collection. Do not delay a clinically indicated urate sample for an invented post-dose waiting period.

### Component 4: Phosphate Binders (Targeted Approach)

**If hyperphosphatemia develops (PO4 \>4.5 mg/dL):**

| Binder | Mechanism | Dosing | Notes |
|----|----|----|----|
| **Aluminum hydroxide** | Binds PO4 in GI tract | 15–30 mL TID-QID | Caution: Al accumulation in renal failure |
| **Calcium carbonate** | Binds PO4; also provides Ca | 1–2 g elemental Ca TID | Use cautiously (Ca × PO4 product). Avoid if already hypocalcemic |
| **Sevelamer** | Non-metal binder | 2.4–4.8 g/day divided | Preferred in severe renal disease; no hypercalcemia risk |
| **CRRT** | Most effective | During dialysis | See dialysis section below |

**Strategy:** If initial PO4 \<5 mg/dL, defer binders; recheck in 4 hours. If PO4 rising rapidly, consider CRRT early.

### Component 5: Allopurinol as Adjunct (When to Use)

**Current role of allopurinol (2026):** - **Intermediate-risk patients** without absolute need for rasburicase - **Cost considerations** (if rasburicase unavailable or not covered) - **Chronic prevention** (after acute TLS phase controlled, allopurinol for maintenance)

**Do NOT use allopurinol as monotherapy** for high-risk patients expecting high tumor burden.

------------------------------------------------------------------------

## MANAGEMENT OF ESTABLISHED TUMOR LYSIS SYNDROME

### Clinical Scenario: Day 1–2 Post-Chemo, Labs Show Cairo-Bishop Positive

    Patient with TLS-level labs (K 6.5, PO4 5.0, uric acid 9.0, Ca 6.8)
        ↓
    IMMEDIATE ASSESSMENT:
    ├─ Continuous cardiac monitoring (peaked T-waves, AV block?)
    ├─ Airway/breathing/circulation assessment
    ├─ Urine output assessment (oliguria = bad sign)
    └─ Check previous baseline labs (acute vs. chronic TLS pattern)
        ↓
    HYPERKALEMIA FIRST — MOST URGENT:

#### Hyperkalemia Management \[1\]

**Board Point:** **HYPERKALEMIA IS THE LIFE-THREATENING EMERGENCY IN TLS** (not hypocalcemia or hypouricemia).

| Intervention | Mechanism | Onset | Duration | Indication |
|----|----|----|----|----|
| **Calcium gluconate** | Stabilizes cardiac membrane | 1–3 min | 30–60 min | K \>6.0 with ECG changes (peaked T, QRS widening) — **FIRST-LINE** |
| **Insulin + Dextrose** | Drives K intracellularly | 10–20 min | 4–6 hours | K \>6.0 without ECG changes; used with Ca gluconate if symptomatic |
| **Albuterol** (nebulized or IV) | Beta-2 agonist → K shift | 30 min | 2–4 hours | Adjunct; less reliable in TLS |
| **Sodium bicarbonate** | Alkalinization shifts K into cells | 30 min–1 hr | 2–4 hours | Use cautiously (worsens PO4 precipitation if high) |
| **Kayexalate** | GI potassium binding | 4–24 hours | Slow | Slower onset; reserve for chronic hyperkalemia management |
| **Dialysis (CRRT, HD)** | Direct K removal | 30 min–1 hr | Ongoing | **GOLD STANDARD** if high-risk features; see below |

**Dosing (from UpToDate/standard protocols):**

    CALCIUM GLUCONATE: 10 mL of 10% solution (10 grams) IV over 2–5 min
    └─ Can repeat q5–10 min if ECG remains abnormal
    └─ Target: Normalize ECG

    INSULIN + DEXTROSE:
    ├─ Insulin: 10 units IV push
    ├─ Dextrose: 25 grams (50 mL of 50% solution) IV
    └─ Recheck K+ in 20 min; repeat if K still >6.0

    ALBUTEROL: 10–20 mg nebulized over 10 min OR 0.5 mg IV

#### Hyperphosphatemia & Hypocalcemia Management

**Key Point:** **DO NOT automatically treat hypocalcemia** unless symptomatic (seizure, tetany, QT prolongation).

**Rationale:** Calcium supplementation + high phosphate → calcium-phosphate precipitation in soft tissues (kidneys, heart, vessels), worsening kidney injury.

**Strategy:**

    Hypocalcemia (Ca <7.0 mg/dL) detected
        ↓
    Symptomatic? (tetany, seizures, QT >500 ms)
        ├─ YES → Give calcium gluconate 10 mL of 10% IV slowly (1–2 min)
        │         Can repeat q5 min if symptoms persist
        └─ NO → OBSERVE; Do NOT treat
        ↓
    Regardless of Ca level:
    ├─ Lower phosphate (see Component 4 above): Phosphate binders or CRRT
    ├─ Check Ca × PO4 product (goal <60–70)
    └─ Recheck Ca in 4 hr; treat only if becomes symptomatic

**Why this works:** As phosphate falls (from binders or dialysis), secondary hypocalcemia spontaneously improves without exogenous Ca supplementation.

#### Hyperuricemia & Uric Acid Nephropathy Management

**If uric acid \>8 mg/dL + AKI:**

    Uric acid nephropathy suspected (high UA, AKI, low UOP, muddy urine)
        ↓
    IMMEDIATE:
    ├─ Aggressive NS hydration (2–3 L/m²/day) if not already
    ├─ Rasburicase 0.2 mg/kg IV if not yet given
    ├─ Hold allopurinol (if on it) until post-rasburicase
    └─ Alkalinize urine?
        └─ TRADITIONAL: Sodium bicarbonate to target urine pH >6.5
        └─ MODERN: NOT recommended due to PO4 precipitation risk
        └─ CURRENT: Rare indication; CRRT preferred
        ↓
    Monitor:
    ├─ Uric acid level at 4 hr post-rasburicase (expect drop to <3 mg/dL)
    ├─ Cr trend: Expect improvement over 24–48 hr if urate oxidase working
    └─ UOP: Target 100–200 mL/hr with hydration
        ↓
    If improving:
    └─ Continue hydration; repeat rasburicase PRN if UA rises >8 again
        ↓
    If worsening (Cr still rising, UOP <50 mL/hr):
    └─ CRRT indicated (see below)

------------------------------------------------------------------------

## DIALYSIS IN TUMOR LYSIS SYNDROME

### When to Initiate Dialysis

**Indications for dialysis in TLS:**

| Indication | Threshold | Action |
|----|----|----|
| **Hyperkalemia** | K \>6.5 refractory to medical mgmt OR symptomatic ECG changes | Urgent dialysis (CRRT preferred) |
| **Fluid overload** | Pulmonary edema, HTN unresponsive to meds | CRRT with ultrafiltration |
| **Severe AKI** | Cr \>3–4, declining UOP \<50 mL/hr despite hydration | CRRT or HD |
| **Hyperphosphatemia** | PO4 \>6–7 mg/dL refractory to binders | CRRT (more efficient clearance) |
| **Oliguria** | UOP \<200 mL/day for \>24 hr post-chemo | Assess hydration adequacy; start CRRT if truly oliguric |

### CRRT vs. Hemodialysis in TLS \[1\]

| Feature | CRRT | Hemodialysis |
|----|----|----|
| **Uric acid clearance** | Continuous; excellent | Intermittent; good per session |
| **Phosphate clearance** | Continuous; excellent | Intermittent but efficient |
| **Potassium clearance** | Continuous; prevents rebound | Excellent but post-dialysis rebound K rise possible |
| **Hemodynamic tolerance** | Better (slower, continuous) | Difficult if hypotensive (shock from massive cell death) |
| **Volume removal** | Gradual, controlled | Rapid; risk of hypovolemia |
| **Availability** | ICU-based | Can be done in dialysis unit |
| **Preferred indication** | **HIGH RISK, massive tumor burden, hypotensive** | Hemodynamically stable, smaller dialysis centers |

**Recommendation:** **CRRT is preferred in TLS** due to superior hemodynamic tolerance and continuous solute clearance.

**CRRT modality in TLS:** - **CVVHD (continuous veno-venous hemodialysis)** — if blood flow adequate; dialysate rate 1–2 L/hr - **CVVHDF (hemodiafiltration)** — combines dialysis + convection; slightly superior clearance - **Avoid SCUF alone** — insufficient solute clearance; need dialysis component

------------------------------------------------------------------------

## SPECIAL SCENARIOS IN TLS

### Spontaneous TLS (Before Chemotherapy)

**Definition:** TLS occurring from natural tumor necrosis **without chemotherapy initiation**.

**Incidence:** 5–15% of high-risk tumors (Burkitt, ALL, high-grade NHL)

**Clinical presentation:** Patient presents with newly diagnosed malignancy already meeting Cairo-Bishop criteria; Cr elevated from outset

**Management:** Identical to chemotherapy-induced TLS; aggressive hydration, rasburicase, dialysis PRN. Begin chemo when metabolically stable.

**Prognosis:** Often worse than chemotherapy-induced TLS (massive tumor burden); higher dialysis requirement.

### TLS from Targeted Therapy (e.g., Venetoclax in CLL)

**Emerging issue:** Targeted agents (especially venetoclax, a BCL-2 inhibitor) can trigger massive TLS comparable to chemotherapy.

**Risk factors:** CLL with high tumor burden, early in venetoclax treatment (first week)

**Prevention & management:** Same as chemotherapy-induced TLS; rasburicase, aggressive hydration, early dialysis if needed.

------------------------------------------------------------------------

## LONG-TERM RENAL OUTCOMES IN TLS SURVIVORS

### Recovery from TLS-Associated AKI

**Prognosis:** 70–80% of TLS patients who survive acute episode have **complete renal recovery** (Cr returns to baseline within weeks to months).

**Predictors of persistent renal dysfunction:** - Severity of initial AKI (Cr \>3–4 with dialysis dependence) - Duration of oliguria (\>5–7 days) - Baseline CKD - Concurrent nephrotoxic agents (especially cisplatin in ALL protocols)

### Chronic CKD in TLS Survivors

**Incidence of lasting CKD:** 10–20% of TLS survivors

**Mechanism:** - Residual tubular damage (uric acid crystal deposition) - Contrast-induced nephropathy (if imaging done acutely) - Cisplatin co-exposure (in ALL/AML regimens)

**Management:** Annual Cr/eGFR assessment in TLS survivors; aggressive CKD prevention (BP control, ACE-I/ARB, avoid NSAIDs).

------------------------------------------------------------------------

## SUMMARY: CLINICAL MANAGEMENT PEARLS

**Board Points to Remember:**

1.  **Prevention \>\>\> Treatment:** Identify high-risk patients immediately; begin rasburicase + aggressive hydration before chemo
2.  **Hyperkalemia is LIFE-THREATENING:** It’s the symptom that causes sudden death, not hypocalcemia or hyperuricemia
3.  **Calcium supplementation is dangerous in TLS:** Avoid unless symptomatic; phosphate lowering is key
4.  **Rasburicase is now standard:** Faster, more effective than allopurinol; check G6PD status before use
5.  **CRRT is preferred dialysis:** Continuous clearance, better hemodynamic tolerance in critically ill TLS patients
6.  **Early dialysis saves lives:** Don’t wait for “maximal medical management”; start CRRT if oliguria develops
7.  **Spontaneous TLS is real:** Cancer patients present with TLS already established; recognize and treat urgently
8.  **Cairo-Bishop has limitations:** Spontaneous TLS not captured by criteria; clinical judgment necessary

------------------------------------------------------------------------

## RELATED RESOURCES & FURTHER READING

- hematologic malignancies kidney review — Renal complications in ALL, Burkitt, NHL
- Acute Kidney Injury Hub — AKI management principles, dialysis indications
- Electrolyte Acid Base Hub — Detailed hyperkalemia, hyperphosphatemia management
- Dialysis Renal Replacement Hub — CRRT technical details, complications
- Medications Toxicology Hub — Drug-related nephrotoxicity in cancer patients

------------------------------------------------------------------------

## 📚 CITED REFERENCES

\[1\] **Cairo MS, Bishop M.** Tumour lysis syndrome: new therapeutic strategies and classification. *Br J Haematol.* 2004;127(1):3-11. [PMID: 15384972](https://pubmed.ncbi.nlm.nih.gov/15384972/). *— Foundational Cairo-Bishop classification system for TLS (laboratory vs clinical TLS; staging by severity).*

\[2\] **Coiffier B, Altman A, Pui CH, Younes A, Cairo MS.** Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. *J Clin Oncol.* 2008;26(16):2767-2778. [PMID: 18509186](https://pubmed.ncbi.nlm.nih.gov/18509186/). *— International TLS expert panel consensus guidelines on risk stratification, prophylaxis (allopurinol, rasburicase), and treatment. Still the current standard of care framework.*

\[3\] **Howard SC, Jones DP, Pui CH.** The tumor lysis syndrome. *N Engl J Med.* 2011;364(19):1844-1854. [PMID: 21561350](https://pubmed.ncbi.nlm.nih.gov/21561350/). *— Comprehensive NEJM clinical practice review covering pathophysiology, prevention, and treatment.*

\[4\] **Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD.** Preventing and Managing Toxicities of High-Dose Methotrexate. *Oncologist.* 2016;21(12):1471-1482. [PMID: 27496039](https://pubmed.ncbi.nlm.nih.gov/27496039/). *— Adjacent reference relevant to TLS in malignancies treated with HD-MTX; not cited in original lecture but relevant to onco-nephrology TLS management context.*

------------------------------------------------------------------------

**Last Updated:** 2026-02-28 **Review Cycle:** Annually or upon new TLS management guidelines **Author Perspective:** Onco-nephrology clinical practice, board review emphasis, ICU-based acute management

### Also on this topic

The same subject at other levels of depth.

- **Lecture:** [🚨 Tumor Lysis Syndrome (TLS)](https://urinenephrology.org/2025_UDPA_Lectures_Live/aki/TLS.html)
- **Interactive case:** [Tumor Lysis Syndrome](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case12_enhanced.html)
- **Student handout:** [Student Handout: Tumor Lysis Syndrome](https://urinenephrology.org/student-resources/advanced/tumor-lysis-syndrome-student-handout.html)


---

[Website version](https://urinenephrology.org/mastery/onconephrology/tumor-lysis-syndrome-comprehensive-review.html) · Markdown synchronized October 3, 2026.